Analytical Data
-
Gene name
MIEN1
- Application
-
Alternative Names
MIEN1;C17orf37;RDX12;XTP4;Migration and invasion enhancer 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BRT3
-
Expression Region
1-112aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMSGEPGQ TSVAPPPEEV EPGSGVRIVV EYCEPCGFEA TYLELASAVK EQYPGIEIES RLGGTGAFEI EINGQLVFSK LENGGFPYEK DLIEAIRRAS NGETLEKITN SRPPC
-
Molecular Weight
15 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MIEN1 (Malignant Cell Invasion 1) is a protein that has garnered attention in cancer research due to its potential role in tumor progression and metastasis. Initially identified in the context of malignant cell behavior, MIEN1 is believed to influence various cellular processes, including cell adhesion, migration, and invasion, which are critical for cancer spread. Its overexpression has been linked with poor prognosis in several cancers, suggesting that MIEN1 may serve as a biomarker for malignancy. Furthermore, research indicates that MIEN1 may interact with key signaling pathways involved in cancer progression, making it a viable target for therapeutic interventions. Understanding the molecular mechanisms of MIEN1 could facilitate the development of novel strategies aimed at inhibiting tumor growth and dissemination. Recent studies have begun to explore the role of MIEN1 in the tumor microenvironment and its potential implications in cancer therapy, highlighting the importance of this protein in oncological research. The ongoing investigation of MIEN1 aims to elucidate its functional role in cancer biology and to evaluate its potential as a therapeutic target or biomarker in clinical settings.
